View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 5, 2017

Pfizer acquires licensing rights for Basilea’s Cresemba in China

Pfizer has signed an agreement with Switzerland-based Basilea Pharmaceutica for the exclusive development and commercialisation rights to Cresemba (isavuconazole) in China and the Asia Pacific region.

Pfizer has signed an agreement with Switzerland-based Basilea Pharmaceutica for the exclusive development and commercialisation rights to Cresemba (isavuconazole) in China and the Asia Pacific region.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

Developed to treat adults with invasive aspergillosis and mucormycosis, Cresemba is an intravenous (IV), oral azole anti-fungal and active agent of prodrug isavuconazonium sulfate.

The firms previously signed an agreement in July, under which Pfizer obtained exclusive commercialisation rights for Cresemba in Europe, except Nordic countries.

Pfizer is currently marketing the drug in Austria, France, Germany, Italy, UK and Spain, and plans to launch in other countries over time.

The latest deal provides the firm with rights to develop, distribute and commercialise Cresemba in China and 16 Asia Pacific countries, except Japan.

“Pfizer is currently marketing the drug in Austria, France, Germany, Italy, UK and Spain, and plans to launch in other countries over time.”

Pfizer APAC, Greater China and Global Brands global president Suneet Varma said: “We believe our extensive geographic footprint in APAC and China, together with our expertise in successfully commercialising innovative medicines, will help enable us to continue to address the unmet medical needs of patients, especially in the area of anti-infectives.”

The US Food and Drug Administration (FDA) approved Cresemba in March 2015 for invasive aspergillosis and mucormycosis treatment in patients aged 18 and above.

The drug received the European centralised marketing authorisation in October of the same year to treat adults with invasive aspergillosis and for mucormycosis patients who cannot use amphotericin B.

It has orphan drug designation in both countries, and is commercialised by Astellas Pharma in the US.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology